TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05942911
Drug: IHL-675A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
Study: NCT05942911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
Study: NCT05554237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06066060
Drug: JMKX000623
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMKX000623, administered orally ;
Study: NCT05061251
Drug: BAY 2402234
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
Study: NCT06110923
Drug: D091
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once administration of Investigational Product per day
Study: NCT05102149
Drug: PB-201 matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
Study: NCT06155760
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg of prednisolone plus standard medical therapy for 60 days
Study: NCT06155760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02590523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral placebo injection with BSS during cataract surgery
Study: NCT06049290
Drug: LBL-034 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose - MTD; Q2W; intravenous infusion
Study: NCT05371184
Drug: L-Glutamine, Oral Powder for Reconstitution
Normalized name: L-Glutamine, oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
Study: NCT04838743
Drug: IDegLira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study.
Study: NCT05967520
Drug: JMKX000189
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMKX000189 will be administered orally once a day
Study: NCT05967520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally once a day
Study: NCT00000875
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04841720
Drug: HSK16149
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);
Study: NCT05110040
Drug: immunosuppressive agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with TAO recruited in this study will administrated with immunosuppressive agent per day
Study: NCT05242445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via SC injection or as an IV infusion.
Study: NCT06373042
Drug: Intraarterial and intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial and intravenous placebo after endovascular thrombectomy
Study: NCT05027516
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
Study: NCT03097796
Drug: PUL-042
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUL-042 Inhalation Solution
Study: NCT05398393
Drug: lipid lowering drugs (e.g. Atorvastatin and amlodipine.)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
Study: NCT05734794
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
Study: NCT06369350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule will be given for up to 31 days.
Study: NCT05860699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo made by the same manufacturer to look like the active pills
Study: NCT05860699
Drug: Half dose CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
Study: NCT05860699
Drug: Full dose CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
Study: NCT05290558
Drug: Placebo Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Study: NCT05779579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level A of placebo
Study: NCT04927572
Drug: FMX114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT06365515
Drug: Levodopa administration
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.
Study: NCT06365515
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered as the placebo-controlled condition.
Study: NCT06170827
Drug: AIO-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIO-001 Solution for SC injection.
Study: NCT05450458
Drug: KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA
Approvals — FDA: no, EMA: no, PMDA: no
Description: KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
Study: NCT06734702
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks for 2 cycles.
Study: NCT00987233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Study: NCT05246007
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
Study: NCT05247996
Drug: Multi-target Drug Therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
Study: NCT05247996
Drug: Immunocheckpoint Inhibitor Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
Study: NCT05921968
Drug: Intravenous iron sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose)~o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg
Study: NCT05275894
Drug: Antibiotic treatment (Metronidazole)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).
Study: NCT04798976
Drug: neoadjuvant/adjuvant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy/endocrine therapy/surgery/radiotherapy
Study: NCT05674422
Drug: total neoadjuvant therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
Study: NCT05119920
Drug: Placebo Ophthalmic Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ophthalmic Topical Cream
Study: NCT04914741
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
Study: NCT04914741
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
Study: NCT04914741
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 100mg orally on Days 1-5 of every 21-day cycle
Study: NCT05657704
Drug: The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
Study: NCT04976738
Drug: Cybis™ 10:25 THC:CBD oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
Study: NCT06451172
Drug: ASO
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
Study: NCT05510843
Drug: THB001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsules for oral administration
Study: NCT06734130
Drug: Androgen Receptor Signal Inhibitor (ARSI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of the standard of care ARSI will be at the discretion of the treating physician.
Study: NCT05889351
Drug: Vehicle gel, 4 + 4 applications or 4 + 2 applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm/placebo
Study: NCT06385808
Drug: MTBF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2.
Study: NCT06254482
Drug: PTC518
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC518 will be administered per dose and schedule specified in the arm.
Study: NCT04734210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical vehicle solution
Study: NCT06580678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application of Water for Injection
Study: NCT05046795
Drug: Placebo inhalation solution QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06331884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of placebo
Study: NCT04535401
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04535401
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002434
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05102396
Drug: Topical placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive topical placebo spray.
Study: NCT05430711
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
Study: NCT05265130
Drug: YiQiFuMai
Approvals — FDA: no, EMA: no, PMDA: no
Description: YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
Study: NCT05265130
Drug: 0.9% Normal Saline 250ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline 250ml IV, about 40 drops per min.
Study: NCT06553950
Drug: Mandibular stabilization splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
Study: NCT05739877
Drug: DA-1229_01 2.5/500mg (Before)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05739877
Drug: DA-1229_01 2.5/500mg (After)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT04371952
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison of doxycycline 200 mg/day to placebo
Study: NCT04371952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo : lactose, 380 mg/gélule
Study: NCT06167187
Drug: Ketorolac and fentanyl
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
Study: NCT05356741
Drug: AMX-818
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as IV infusion
Study: NCT00000643
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05003089
Drug: BAY1834845
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral.
Study: NCT05003089
Drug: BAY1830839
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral.
Study: NCT05003089
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral.
Study: NCT05003089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral.
Study: NCT06066203
Drug: GNC-035
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
Study: NCT06433518
Drug: recombinant hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Group: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.~Control Group: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.~All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.~The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.~Primary and secondary outcomes will be compared between the two groups.
Study: NCT05783193
Drug: TGIR (Traditional Gastrointestinal Remedy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGIR botanical formulation
Study: NCT05783193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT06011291
Drug: SYH2051 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
Study: NCT05342467
Drug: Dinoprostone 3 mg
Normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
Study: NCT04521335
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
Study: NCT05902819
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
Study: NCT05902819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
Study: NCT05765487
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Active or experimental ingredients
Study: NCT05765487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with only L-arginine
Study: NCT04900038
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
Study: NCT04847518
Drug: Kan Jang capsules
Normalized name: ASIAN GINSENG 500 mg in 500 mg ORAL CAPSULE [Cheong-Kwan-Jang Korean HongSam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule contains a fixed combination of proprietary~* Andrographis paniculata Nees. herb, native extract, DER native 4,5-8,0 :1 260 mg (Diterpene lactones andrographolide and 14-deoxy, 11,12- didehydroadnrograholide) 15-20 mg~* Eleutherococcus senticosus (Rupr. et Maxim) Harms, root, native extract DER native 17-30:1 : 11.4 mg and other inactive excipients (Polycristalline cellulose, Magnesium stearate).
Study: NCT05080959
Drug: Naropin 150 MG Per 20 ML Injection
Normalized name: Naropin 150 MG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose
Study: NCT05080959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose
Study: NCT05907993
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
Study: NCT05355974
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine continuous infusion at 0.10 mcg/kg/min
Study: NCT05355974
Drug: Lactated Ringers, Intravenous
Normalized name: Lactated Ringers, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mL infusion run at 999mL/hr
Study: NCT05355974
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mL infusion run at 999mL/hr
Study: NCT05355974
Drug: Plasma-lyte
Normalized name: Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mL infusion run at 999mL/hr
Study: NCT02649530
Drug: WNT974
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04883658
Drug: CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04339270
Drug: Azithropycin according to symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed.